Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hung Hung

Showing results (471-480 of 563) with videos related to

Pageof 57
Sort By:
Journal of Personalized Medicine|August 27, 2021
Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative ResectionYen-Po Lin, Shu-Hsien Lin, Chih-Chi Wang, et al.
Journal of Hepatology|June 15, 2015
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized studyAnn-Lii Cheng, Yoon-Koo Kang, Aiwu Ruth He, et al.
American Journal of Cancer Research|November 18, 2024
A new model based on preoperative AFP, albumin, and tumor burden score for predicting microvascular invasion in early-stage HCCYuan-Sheng Chang, Mu-Jung Tsai, Chieh-Jui Tsai, et al.
European Journal of Cancer (Oxford, England : 1990)|January 12, 2010
Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosisYuan-Hung Kuo, Sheng-Nan Lu, Chao-Long Chen, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2016
Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapyCheng-Kun Wu, Kuo-Chin Chang, Chao-Hung Hung, et al.
Clinical and Translational Gastroenterology|June 30, 2017
A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute ExacerbationChao-Hung Hung, Kwong-Ming Kee, Chih-Hung Chen, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2015
Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbationChao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 1, 2025
Proton beam therapy versus trans-arterial chemoembolization for BCLC stage B hepatocellular carcinoma-a propensity-matched analysisTzu-Ting Liu, Bing-Shen Huang, Yu-Ming Wang, et al.
Cancers|May 13, 2020
On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular CarcinomaHung-Wei Wang, Hsueh-Chou Lai, Tsung-Hui Hu, et al.
Journal of Surgical Oncology|July 23, 2008
Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patientsPo-Lin Tseng, Ming-Hong Tai, Chao-Cheng Huang, et al.
Pageof 57

Showing results (471-480 of 563) with videos related to

Sort By:
Pageof 57
Journal of Personalized Medicine|August 27, 2021
Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative ResectionYen-Po Lin, Shu-Hsien Lin, Chih-Chi Wang, et al.
Journal of Hepatology|June 15, 2015
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized studyAnn-Lii Cheng, Yoon-Koo Kang, Aiwu Ruth He, et al.
American Journal of Cancer Research|November 18, 2024
A new model based on preoperative AFP, albumin, and tumor burden score for predicting microvascular invasion in early-stage HCCYuan-Sheng Chang, Mu-Jung Tsai, Chieh-Jui Tsai, et al.
European Journal of Cancer (Oxford, England : 1990)|January 12, 2010
Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosisYuan-Hung Kuo, Sheng-Nan Lu, Chao-Long Chen, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2016
Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapyCheng-Kun Wu, Kuo-Chin Chang, Chao-Hung Hung, et al.
Clinical and Translational Gastroenterology|June 30, 2017
A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute ExacerbationChao-Hung Hung, Kwong-Ming Kee, Chih-Hung Chen, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2015
Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbationChao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 1, 2025
Proton beam therapy versus trans-arterial chemoembolization for BCLC stage B hepatocellular carcinoma-a propensity-matched analysisTzu-Ting Liu, Bing-Shen Huang, Yu-Ming Wang, et al.
Cancers|May 13, 2020
On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular CarcinomaHung-Wei Wang, Hsueh-Chou Lai, Tsung-Hui Hu, et al.
Journal of Surgical Oncology|July 23, 2008
Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patientsPo-Lin Tseng, Ming-Hong Tai, Chao-Cheng Huang, et al.
Pageof 57